MedTrace Logo

Humoral Immunity Against SARS-CoV-2 in Liver Transplanted Patients After COVID-19 in Comparison With Immunocompetent Patients

NCT04410471 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2020-06-02

No results posted yet for this study

Summary

This is a prospective study analyzing the development of humoral immune response against SARS-Cov-2 in patients with previous Covid19: the aim is to compare the incidence, titration and evolution of IgG an IgM in a prospective cohort of liver transplant patients surviving to the first wave of Covid19, in comparison to not inmmunossupressed patients.

Conditions

  • Liver Transplant Infection
  • Covid19
  • Mortality
  • Immune Response

Interventions

DIAGNOSTIC_TEST

CLIA of IgG and IgM against SARS-Cov-2

Report of clinical data

Sponsors & Collaborators

  • Magdalena Salcedo

    lead OTHER

Principal Investigators

  • Magdalena Salcedo, MD PhD · Liver Transplantation Unit

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-29
Primary Completion
2020-05-29
Completion
2021-06-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04410471 on ClinicalTrials.gov